WHAT IS BRIUMVI?
BRIUMVI is the only B‑cell therapy approved for people with RMS that is administered in a 1‑HOUR INFUSION, TWICE PER YEAR.*
*Following the starting dose
WHAT IS BRIUMVI?
BRIUMVI is the only B‑cell therapy approved for people with RMS that is administered in a 1‑HOUR INFUSION, TWICE PER YEAR.*
*Following the starting dose
WHAT IS BRIUMVI?
BRIUMVI is the only B‑cell therapy approved for people with RMS that is administered in a 1‑HOUR INFUSION, TWICE PER YEAR.*
*Following the starting dose
People featured on this page are taking BRIUMVI and have been compensated by TG Therapeutics for their time.
People featured on this page are taking BRIUMVI and have been compensated by TG Therapeutics for their time.
Why Choose BRIUMVI
Proven results in 2 separate, 2‑year clinical studies
Reduced relapses by 59% in Study 1 (in Study 2 by 49%) compared to teriflunomide†
Significantly reduced brain lesions on magnetic resonance imaging (MRI)
Established safety profile
Tested in 2 clinical studies with more than 1,000 people, of whom 545 were given BRIUMVI
Overall infection rates of BRIUMVI and teriflunomide were similar. Most were mild to moderate and consisted of upper respiratory tract infections and urinary tract infections
1‑hour, twice‑per‑year* infusion option
The only available 1‑hour, twice-per-year* IV infusion following the starting dose
Post-infusion monitoring is at your healthcare provider’s discretion and is not required after your third infusion and beyond (unless you have experienced an infusion-related reaction and/or signs of hypersensitivity with your current or prior infusions)
*Following the starting dose.
†Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.
IV, intravenous
Proven results in 2 separate, 2‑year clinical studies
Reduced relapses by 59% in Study 1 (in Study 2 by 49%) compared to teriflunomide†
Significantly reduced brain lesions on magnetic resonance imaging (MRI)
Established safety profile
Tested in 2 clinical studies with more than 1,000 people, of whom 545 were given BRIUMVI
Overall infection rates of BRIUMVI and teriflunomide were similar. Most were mild to moderate and consisted of upper respiratory tract infections and urinary tract infections
1‑hour, twice‑per‑year* infusion option
The only available 1‑hour, twice-per-year* IV infusion following the starting dose
Post‑infusion monitoring is at your healthcare provider’s discretion and is not required after your third infusion and beyond (unless you have experienced an infusion‑related reaction and/or signs of hypersensitivity with your current or prior infusions)
*Following the starting dose.
†Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.
IV, intravenous
Looking for more information on BRIUMVI?
Looking for more information on BRIUMVI?
Looking for more information on BRIUMVI?
What is RMS, and how does BRIUMVI work?
What is RMS and how do B cells play a role?
RMS is when a person’s own immune system attacks the central nervous system, which includes the brain, spine and optic nerves. The immune system consists of many cells including B cells. In people with RMS, B cells are believed to contribute to the immune system’s attack on myelin—the protective covering around nerves. When myelin is damaged, it can disrupt communication between the brain and the rest of the body.
How does BRIUMVI work?
BRIUMVI is a B-cell therapy designed to specifically target certain B cells and facilitate their removal. Although it is not known exactly how BRIUMVI works, its design is thought to enhance the process by which these specific B cells are removed.
What does this mean for people living with RMS?
Removing certain B cells plays a very important role in the treatment of RMS. Because BRIUMVI is designed to target only certain B cells, the overall immune system is not affected.
What is RMS and how do B cells play a role?
RMS is when a person’s own immune system attacks the central nervous system, which includes the brain, spine and optic nerves. The immune system consists of many cells including B cells. In people with RMS, B cells are believed to contribute to the immune system’s attack on myelin—the protective covering around nerves. When myelin is damaged, it can disrupt communication between the brain and the rest of the body.
How does BRIUMVI work?
BRIUMVI is a B-cell therapy designed to specifically target certain B cells and facilitate their removal. Although it is not known exactly how BRIUMVI works, its design is thought to enhance the process by which these specific B cells are removed.
What does this mean for people living with RMS?
Removing certain B cells plays a very important role in the treatment of RMS. Because BRIUMVI is designed to target only certain B cells, the overall immune system is not affected.
Medications that target B cells have been available to treat diseases for more than 25 years and are the most widely prescribed type of medication to treat RMS today.
BRIUMVI was approved by the FDA in 2022.
Learn more about the results from the head‑to‑head clinical studies
What to expect on your BRIUMVI
infusion day
Hear from the thousands who are taking on RMS with BRIUMVI
Discover how people living with RMS have included BRIUMVI in their treatment journey.
Hear from the thousands who are taking on RMS with BRIUMVI
Discover how people living with RMS have included BRIUMVI in their treatment journey.
Hear from the thousands who are taking on RMS with BRIUMVI
Discover how people living with RMS have included BRIUMVI in their treatment journey.
INDICATION AND IMPORTANT
SAFETY INFORMATION
Who should not receive BRIUMVI?
What is the most important information I should know about BRIUMVI?
-
- fever
- chills
- headache
- flu-like symptoms
- fast heartbeat
- hives
- itchy skin
- dizziness
-
- feeling faint
- swelling of tongue or throat
- trouble breathing
- wheezing
- nausea
- abdominal pain
- throat irritation
- redness of the face or skin
These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.
- Infection:
- Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.
- Hepatitis B virus (HBV) reactivation: Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.
- Weakened immune system: BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
- Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. PML has been reported with BRIUMVI. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.
- Low immunoglobulins: BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.
Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:
What are the possible side effects of BRIUMVI?
Indication
Stay in the know
Sign up to receive the latest updates and resources for BRIUMVI
Join us for a Multiple Sclerosis (MS) educational event near you
